Minerva Neurosciences (NERV) Research & Development (2013 - 2026)

Minerva Neurosciences has reported Research & Development for 14 years, with the latest figure at $5.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 285.7% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2026 stood at $9.7 million (up 6.14% YoY), and the FY2025 full-year result was $5.8 million, down 51.6% from the prior year.
• Research & Development for Q1 2026 stood at $5.3 million, up from $2.2 million in the prior quarter.
• The five-year high for Research & Development was $5.3 million in Q1 2026, with the low at $925377.0 in Q3 2025.
• Historically, Research & Development has averaged $3.0 million across 5 years, with a median of $2.7 million in 2023.
• Annual changes were most pronounced in 2022 — Research & Development slumped 82.98% — and 2026, when it surged 285.7%.
• Minerva Neurosciences' Research & Development stood at $3.2 million in 2022, then surged by 47.99% to $4.7 million in 2023, then tumbled by 58.0% to $2.0 million in 2024, then advanced by 9.62% to $2.2 million in 2025, then jumped by 141.76% to $5.3 million in 2026.
• The last three Research & Development figures came in at $5.3 million (Q1 2026), $2.2 million (Q4 2025), and $925377.0 (Q3 2025), per Business Quant data.